Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Shreef Said, Alan Dardik & Cassius Iyad Ochoa Chaar. (2023) What are the benefits and drawbacks of statins in carotid artery disease? A perspective review. Expert Review of Cardiovascular Therapy 21:11, pages 763-777.
Read now
Read now
Karina Cunha e Rocha, Beatriz Maria Veloso Pereira & Alice Cristina Rodrigues. (2018) An update on efflux and uptake transporters as determinants of statin response. Expert Opinion on Drug Metabolism & Toxicology 14:6, pages 613-624.
Read now
Read now
Hye In Woo, Suk Ran Kim, Wooseong Huh, Jae-Wook Ko & Soo-Youn Lee. (2017) Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects. Drug Design, Development and Therapy 11, pages 1135-1146.
Read now
Read now
Miao Hu & Brian Tomlinson. (2013) Lipid-lowing pharmacogenomics in Chinese patients. Expert Review of Cardiovascular Therapy 11:8, pages 985-997.
Read now
Read now
Articles from other publishers (44)
Edward Zheng, Paulina Madura, Jakub Grandos, Marlena Broncel, Agnieszka Pawlos, Ewelina Woźniak & Paulina Gorzelak-Pabiś. (2024) When the same treatment has different response: The role of pharmacogenomics in statin therapy. Biomedicine & Pharmacotherapy 170, pages 115966.
Crossref
Crossref
Yuting Zhang, Weijuan Xin, Xiaozhi Hu, Hanqi Wang, Xiaomiao Ye, Caili Xu, Yanyang Nan, Zhengyu Wu, Dianwen Ju & Jiajun Fan. (2023) Inhibition of Hedgehog signaling ameliorates foam cell formation by promoting autophagy in early atherosclerosis. Cell Death & Disease 14:11.
Crossref
Crossref
Ninoslava Lalatović, Maša Ždralević, Tanja Antunović & Snežana Pantović. (2023) Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study. Scientific Reports 13:1.
Crossref
Crossref
K. O. Shnaider, M. L. Maximov, V. A. Baranova & A. A. Nekipelova. (2023) PCSK9 Inhibitor Therapy as an Alternative for Statin Intolerance. Safety and Risk of Pharmacotherapy.
Crossref
Crossref
D. A. Sychev, T. M. Ostroumova, O. D. Ostroumova, A. I. Kochetkov, S. V. Batyukina & E. V. Mironova. (2023) Statin-Induced Myopathy. Safety and Risk of Pharmacotherapy 11:3, pages 252-270.
Crossref
Crossref
Hong Ha Nguyen, Cuc Thi Thu Nguyen, Tran Ngoc Phuong Mai & Phung Thanh Huong. (2023) Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis. Pharmacogenetics and Genomics 33:4, pages 65-78.
Crossref
Crossref
Aymen Shatnawi, Zourayz Kamran & Qusai Al-Share. (2023) Pharmacogenomics of lipid-lowering agents: the impact on efficacy and safety. Personalized Medicine 20:1, pages 65-86.
Crossref
Crossref
Donna S. Whitlon. (2022) Statins and hearing. Hearing Research 425, pages 108453.
Crossref
Crossref
Mohammed Dashti, Abdullah Al-Matrouk, Arshad Channanath, Fahd Al-Mulla & Thangavel Alphonse Thanaraj. (2022) Frequency of functional exonic single-nucleotide polymorphisms and haplotype distribution in the SLCO1B1 gene across genetic ancestry groups in the Qatari population. Scientific Reports 12:1.
Crossref
Crossref
Chiara Macchi, Veronica Bonalume, Maria Francesca Greco, Marta Mozzo, Valentina Melfi, Cesare R. Sirtori, Valerio Magnaghi, Alberto Corsini & Massimiliano Ruscica. (2022) Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability—Evidence from ApoE-/- Mice. International Journal of Molecular Sciences 23:10, pages 5415.
Crossref
Crossref
Pierandrea Vinci, Emiliano Panizon, Letizia Maria Tosoni, Carla Cerrato, Federica Pellicori, Filippo Mearelli, Chiara Biasinutto, Nicola Fiotti, Filippo Giorgio Di Girolamo & Gianni Biolo. (2021) Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. International Journal of Molecular Sciences 22:21, pages 11687.
Crossref
Crossref
Ping Siu Kee, Paul Ken Leong Chin, Martin A. Kennedy & Simran D. S. Maggo. (2020) Pharmacogenetics of Statin-Induced Myotoxicity. Frontiers in Genetics 11.
Crossref
Crossref
Chalitpon Na nakorn, Jariya Waisayarat, Charungthai Dejthevaporn, Pornpen Srisawasdi, Sansanee Wongwaisayawan & Chonlaphat Sukasem. (2020) Genetic Variations and Frequencies of the Two Functional Single Nucleotide Polymorphisms of SLCO1B1 in the Thai Population. Frontiers in Pharmacology 11.
Crossref
Crossref
Zexuan Wu, Dexi Wu, Jingzhou Jiang, Ailan Chen, Dong-Dan Zheng, Jianhao Li, Yugang Dong & Yili Chen. (2020) Efficacy and safety of xuezhikang once per day versus two times per day in patients with mild to moderate hypercholesterolaemia (APEX study): a protocol for a multicentre, prospective randomised controlled, open-label, non-inferiority study. BMJ Open 10:5, pages e034585.
Crossref
Crossref
Guangyan Mu, Qian Xiang, Shuang Zhou, Zhiyan Liu, Litong Qi, Jie Jiang, Yanjun Gong, Qiufen Xie, Zining Wang, Hanxu Zhang, Yong Huo & Yimin Cui. (2020) Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials. Advances in Therapy 37:4, pages 1496-1521.
Crossref
Crossref
Saman Bahrambeigi, Mahdi Rahimi, Bahman Yousefi & Vahid Shafiei‐Irannejad. (2019) New potentials for 3‐hydroxy‐3‐methyl‐glutaryl‐coenzymeA reductase inhibitors: Possible applications in retarding diabetic complications. Journal of Cellular Physiology 234:11, pages 19393-19405.
Crossref
Crossref
Stelina Alkagiet, George Giannakoulas, Apostolos I. Hatzitolios & Konstantinos Tziomalos. (2019) The Role of Statins in the Management of Heart Failure with Preserved Ejection Fraction. Current Pharmacology Reports 5:4, pages 210-213.
Crossref
Crossref
Lee M. Tatham, Neill J. Liptrott, Steve P. Rannard & Andrew Owen. (2019) Long-Acting Injectable Statins—Is It Time for a Paradigm Shift?. Molecules 24:15, pages 2685.
Crossref
Crossref
Sara Bakr Abd El-Kader, Aida Ahmed Said Guemei, Mervat Kamel Barakat, Iman Hassan Diab & Magdy Helmy Megallaa. (2019) Assessment of the Effect of HMGCR Variant Alleles on Response to Atorvastatin Treatment in Type 2 Diabetic Egyptian Patients. Egyptian Journal of Basic and Clinical Pharmacology 9.
Crossref
Crossref
Tomás Zambrano, Kathleen Saavedra & Luis A. Salazar. 2019. Pharmacoepigenetics. Pharmacoepigenetics
817
825
.
S. Magno, G. Ceccarini, C. Pelosini, R. Jaccheri, J. Vitti, P. Fierabracci, G. Salvetti, G. Airoldi, M. Minale, G. Saponati & F. Santini. (2018) LDL-cholesterol lowering effect of a new dietary supplement: an open label, controlled, randomized, cross-over clinical trial in patients with mild-to-moderate hypercholesterolemia. Lipids in Health and Disease 17:1.
Crossref
Crossref
Baoqing Sun, Luming Li & Xinfu Zhou. (2018) Comparative analysis of the gut microbiota in distinct statin response patients in East China. Journal of Microbiology 56:12, pages 886-892.
Crossref
Crossref
Faisal Mahmood, Tanvir Shahzad, Sabir Hussain, Muhammad Shahid, Muhammad Azeem & Jacques Wery. 2018. Sustainable Agriculture Reviews 32. Sustainable Agriculture Reviews 32
105
133
.
Marleen E. Jansen, T. Rigter, W. Rodenburg, T. M. C. Fleur, E. J. F. Houwink, M. Weda & Martina C. Cornel. (2017) Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity. Frontiers in Pharmacology 8.
Crossref
Crossref
Steven W. Johnson, Dorothea K. Thompson & Brianne Raccor. (2017) Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions. Current Infectious Disease Reports 19:6.
Crossref
Crossref
Elena Arrigoni, Marzia Del Re, Leonardo Fidilio, Stefano Fogli, Romano Danesi & Antonello Di Paolo. (2017) Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. International Journal of Molecular Sciences 18:1, pages 104.
Crossref
Crossref
Isabel De Castro-Orós, Rosa Solà, Rosa María Valls, Angel Brea, Pilar Mozas, Jose Puzo & Miguel Pocoví. (2016) Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine. PLOS ONE 11:3, pages e0150785.
Crossref
Crossref
Maarten Leusink, N Charlotte Onland-Moret, Paul IW de Bakker, Anthonius de Boer & Anke H Maitland-van der Zee. (2016) Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics 17:2, pages 163-180.
Crossref
Crossref
Kan-kan Wei & Li-rong Zhang. (2015) Interactions Between CYP3A5*3 and POR*28 Polymorphisms and Lipid Lowering Response with Atorvastatin. Clinical Drug Investigation 35:9, pages 583-591.
Crossref
Crossref
Nathan D. Wong, Joanna Chuang, Yanglu Zhao & Paul D. Rosenblit. (2015) Residual dyslipidemia according to low-density lipoprotein cholesterol, non–high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010. Journal of Clinical Lipidology 9:4, pages 525-532.
Crossref
Crossref
Sudarshini RamanathanDaman LangguthTodd A. HardyNidhi GargChris BundellArada Rojana-UdomsartRussell C. DaleThomas RobertsonAndrew L. MammenStephen W. Reddel. (2015) Clinical course and treatment of anti-HMGCR antibody–associated necrotizing autoimmune myopathy. Neurology Neuroimmunology & Neuroinflammation 2:3.
Crossref
Crossref
Paolo Magni, Chiara Macchi, Beatrice Morlotti, Cesare R. Sirtori & Massimiliano Ruscica. (2015) Risk identification and possible countermeasures for muscle adverse effects during statin therapy. European Journal of Internal Medicine 26:2, pages 82-88.
Crossref
Crossref
Jeff Chen, Michael P. Hutchens & Wayne T. Nicholson. 2015. A Case Approach to Perioperative Drug-Drug Interactions. A Case Approach to Perioperative Drug-Drug Interactions
641
644
.
Cesare R. Sirtori. (2014) The pharmacology of statins. Pharmacological Research 88, pages 3-11.
Crossref
Crossref
Hyeongsun Moon, Michelle M. Hill, Matthew J. Roberts, Robert A. Gardiner & Andrew J. Brown. (2014) Statins: protectors or pretenders in prostate cancer?. Trends in Endocrinology & Metabolism 25:4, pages 188-196.
Crossref
Crossref
Massimiliano Ruscica, Monica Gomaraschi, Giuliana Mombelli, Chiara Macchi, Raffaella Bosisio, Franco Pazzucconi, Chiara Pavanello, Laura Calabresi, Anna Arnoldi, Cesare R. Sirtori & Paolo Magni. (2014) Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus. Journal of Clinical Lipidology 8:1, pages 61-68.
Crossref
Crossref
Veronique Verhoeven, Maja Lopez Hartmann, Roy Remmen, Johan Wens, Sandra Apers & Paul Van Royen. (2013) Red yeast rice lowers cholesterol in physicians - a double blind, placebo controlled randomized trial. BMC Complementary and Alternative Medicine 13:1.
Crossref
Crossref
Reijo Laaksonen. (2013) STOMPing forward: Statins, muscle complaints and CK. Atherosclerosis 230:2, pages 256-257.
Crossref
Crossref
Rafael Bitzur, Hofit Cohen, Yehuda Kamari & Dror Harats. (2013) Intolerance to Statins: Mechanisms and Management. Diabetes Care 36:Supplement_2, pages S325-S330.
Crossref
Crossref
Miao Hu & Brian Tomlinson. (2013) Pharmacogenomics of lipid-lowering therapies. Pharmacogenomics 14:8, pages 981-995.
Crossref
Crossref
Minna T. Jänis, Kirill Tarasov, Hung Xuan Ta, Matti Suoniemi, Kim Ekroos, Reini Hurme, Terho Lehtimäki, Hannu Päivä, Marcus E. Kleber, Winfried März, Annik Prat, Nabil G. Seidah & Reijo Laaksonen. (2013) Beyond LDL-C lowering: Distinct molecular sphingolipids are good indicators of proprotein convertase subtilisin/kexin type 9 (PCSK9) deficiency. Atherosclerosis 228:2, pages 380-385.
Crossref
Crossref
Dilek Iusuf, Anita van Esch, Michael Hobbs, Maxine Taylor, Kathryn E. Kenworthy, Evita van de Steeg, Els Wagenaar & Alfred H. Schinkel. (2013) Murine Oatp1a/1b Uptake Transporters Control Rosuvastatin Systemic Exposure Without Affecting Its Apparent Liver Exposure. Molecular Pharmacology 83:5, pages 919-929.
Crossref
Crossref
Dipan A. Desai, Sammy Zakaria & Pamela Ouyang. (2011) Initiation of Statin Therapy: Are There Age Limits?. Current Atherosclerosis Reports 14:1, pages 17-25.
Crossref
Crossref
H. Robert Superko, Kathryn M. Momary & Yonghong Li. (2012) Statins Personalized. Medical Clinics of North America 96:1, pages 123-139.
Crossref
Crossref